Advances in vaccine adjuvants

[1]  G. Dougan,et al.  Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. , 1999, Immunology today.

[2]  N. Lycke,et al.  Immune-stimulating complexes induce an IL-12-dependent cascade of innate immune responses. , 1999, Journal of immunology.

[3]  N. Lycke,et al.  Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity. , 1999, Journal of immunology.

[4]  K. Barnhart,et al.  CpG motifs as immune adjuvants. , 1999, Vaccine.

[5]  D. Putnam,et al.  PLGA microspheres containing plasmid DNA: preservation of supercoiled DNA via cryopreparation and carbohydrate stabilization. , 1999, Journal of pharmaceutical sciences.

[6]  E. Gelfand,et al.  Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. , 1998, Journal of immunology.

[7]  P. Ricciardi-Castagnoli,et al.  Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. , 1998, Science.

[8]  M. Rothe,et al.  Human Toll-like Receptor 2 Confers Responsiveness to Bacterial Lipopolysaccharide , 1998, The Journal of experimental medicine.

[9]  O’Hagan,et al.  Microparticles and polymers for the mucosal delivery of vaccines. , 1998, Advanced drug delivery reviews.

[10]  H. Mischak,et al.  CpG‐DNA‐specific activation of antigen‐presenting cells requires stress kinase activity and is preceded by non‐specific endocytosis and endosomal maturation , 1998, The EMBO journal.

[11]  H. Davis,et al.  CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. , 1998, Journal of immunology.

[12]  A. Gurney,et al.  Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling , 1998, Nature.

[13]  T. Jakob,et al.  Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. , 1998, Journal of immunology.

[14]  C. Kensil,et al.  QS-21: a water-soluble triterpene glycoside adjuvant. , 1998, Expert opinion on investigational drugs.

[15]  I. Barr,et al.  ISCOMs and other saponin based adjuvants. , 1998, Advanced drug delivery reviews.

[16]  M. S. Singh,et al.  Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines. , 1998, Advanced drug delivery reviews.

[17]  Gupta,et al.  Aluminum compounds as vaccine adjuvants. , 1998, Advanced drug delivery reviews.

[18]  Wang,et al.  Targeting immune response induction with cochleate and liposome-based vaccines. , 1998, Advanced drug delivery reviews.

[19]  Newman,et al.  Development of adjuvant-active nonionic block copolymers. , 1998, Advanced drug delivery reviews.

[20]  T. Wilckens.  Steroid Hormones and the T-cell Cytokine Profile , 1998 .

[21]  Z. Moldoveanu,et al.  CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. , 1998, Vaccine.

[22]  R. Vabulas,et al.  Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells , 1998, European journal of immunology.

[23]  M. Salgaller,et al.  Use of cellular and cytokine adjuvants in the immunotherapy of cancer , 1998, Journal of surgical oncology.

[24]  H. Mohri,et al.  Induction of Systemic and Mucosal Immune Responses to Human Immunodeficiency Virus Type 1 by a DNA Vaccine Formulated with QS-21 Saponin Adjuvant via Intramuscular and Intranasal Routes , 1998, Journal of Virology.

[25]  D. McDonald,et al.  Dendritic cells internalize vaccine adjuvant after intramuscular injection. , 1998, Cellular immunology.

[26]  G. Dougan,et al.  Optimism over vaccines administered via mucosal surfaces , 1998, The Lancet.

[27]  R. Gupta,et al.  Rational approaches to reduce adverse reactions in man to vaccines containing tetanus and diphtheria toxoids. , 1998, Vaccine.

[28]  M. Levine,et al.  Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato , 1998, Nature Medicine.

[29]  J. Sprent,et al.  DNA as an Adjuvant: Capacity of Insect DNA and Synthetic Oligodeoxynucleotides to Augment T Cell Responses to Specific Antigen , 1998, The Journal of experimental medicine.

[30]  G. Dougan,et al.  Mucosal Adjuvanticity and Immunogenicity of LTR72, a Novel Mutant of Escherichia coli Heat-labile Enterotoxin with Partial Knockout of ADP-ribosyltransferase Activity , 1998, The Journal of experimental medicine.

[31]  O’Hagan,et al.  Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: the effect of adjuvants on mucosal and serum antibody responses , 1998, Immunology.

[32]  P. van Damme,et al.  Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. , 1998, Vaccine.

[33]  B. Hirst,et al.  Ulex europaeus 1 lectin targets microspheres to mouse Peyer's patch M-cells in vivo. , 1998, Vaccine.

[34]  M. Hedley,et al.  Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses , 1998, Nature Medicine.

[35]  G. Matyas,et al.  Skin immunization made possible by cholera toxin , 1998, Nature.

[36]  Scott D. Putney,et al.  Improving protein therapeutics with sustained-release formulations , 1998, Nature Biotechnology.

[37]  A. Krieg,et al.  CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. , 1998, Journal of immunology.

[38]  J. Orange,et al.  Early Murine Cytomegalovirus (MCMV) Infection Induces Liver Natural Killer (NK) Cell Inflammation and Protection Through Macrophage Inflammatory Protein 1α (MIP-1α)–dependent Pathways , 1998, The Journal of experimental medicine.

[39]  A. Andrianov,et al.  Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine. , 1998, Vaccine.

[40]  G. Dougan,et al.  Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant. , 1998, Vaccine.

[41]  M. Reddish,et al.  Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2 , 1998, Nature Medicine.

[42]  R. Rappuoli,et al.  Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection , 1997, Infection and immunity.

[43]  G. Van Nest,et al.  The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice. , 1997, Vaccine.

[44]  A. Hill,et al.  A protein particle vaccine containing multiple malaria epitopes , 1997, Nature Biotechnology.

[45]  J. Berzofsky,et al.  Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[46]  A. Holder,et al.  Immunization against the murine malaria parasite Plasmodium yoelii using a recombinant protein with adjuvants developed for clinical use. , 1997, Vaccine.

[47]  T. Monath,et al.  Targeted delivery of antigen to hamster nasal lymphoid tissue with M-cell-directed lectins , 1997, Infection and immunity.

[48]  K. Okuda,et al.  HIV‐1‐specific cell‐mediated immune responses induced by DNA vaccination were enhanced by mannan‐coated liposomes and inhibited by anti‐interferon‐γ antibody , 1997, Immunology.

[49]  H. Mohri,et al.  Monophosphoryl lipid A enhances both humoral and cell-mediated immune responses to DNA vaccination against human immunodeficiency virus type 1 , 1997, Infection and immunity.

[50]  F Ambrosch,et al.  Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. , 1997, Vaccine.

[51]  C. Janeway,et al.  A human homologue of the Drosophila Toll protein signals activation of adaptive immunity , 1997, Nature.

[52]  H. Weiner.  Oral tolerance: immune mechanisms and treatment of autoimmune diseases. , 1997, Immunology today.

[53]  G. Dougan,et al.  Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin , 1997, Infection and immunity.

[54]  J. Clegg,et al.  Poly(DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. , 1997, Vaccine.

[55]  D. Granoff,et al.  MF59 adjuvant enhances antibody responses of infant baboons immunized with Haemophilus influenzae type b and Neisseria meningitidis group C oligosaccharide-CRM197 conjugate vaccine , 1997, Infection and immunity.

[56]  N. Lycke,et al.  Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. , 1997, Journal of immunology.

[57]  A. Osterhaus,et al.  Induction of protective immunity against influenza virus in a macaque model: comparison of conventional and iscom vaccines. , 1997, The Journal of general virology.

[58]  Donald E. Chickering,et al.  Biologically erodable microspheres as potential oral drug delivery systems , 1997, Nature.

[59]  P. Couvreur,et al.  Protective immunity against Salmonella typhimurium elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly(DL-lactide-co-glycolide) microspheres , 1997, Infection and immunity.

[60]  D. Rahman,et al.  Salivary, gut, vaginal and nasal antibody responses after oral immunization with biodegradable microparticles. , 1997, Vaccine.

[61]  G. Ott,et al.  Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles. , 1997, Molecular medicine today.

[62]  Joe D. Cohen,et al.  A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. , 1997, The New England journal of medicine.

[63]  R. Rappuoli,et al.  Protease susceptibility and toxicity of heat-labile enterotoxins with a mutation in the active site or in the protease-sensitive loop , 1997, Infection and immunity.

[64]  R. Langer,et al.  Polymerized liposomes as potential oral vaccine carriers: Stability and bioavailability , 1996 .

[65]  O'Hagan Dt,et al.  THE INTESTINAL UPTAKE OF PARTICLES AND THE IMPLICATIONS FOR DRUG AND ANTIGEN DELIVERY , 1996 .

[66]  G. Nest,et al.  MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. , 1996, The Journal of infectious diseases.

[67]  X M Li,et al.  Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. , 1996, Vaccine.

[68]  J. Whittum-Hudson,et al.  Oral immunization with an anti–idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection , 1996, Nature Medicine.

[69]  L. Bergmeier,et al.  Mucosal or targeted lymph node immunization of macaques with a particulate SIVp27 protein elicits virus-specific CTL in the genito-rectal mucosa and draining lymph nodes. , 1996, Journal of immunology.

[70]  J. Carlson,et al.  MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. , 1996, Vaccine.

[71]  G. Dougan,et al.  Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant , 1996, Infection and immunity.

[72]  B. McBride,et al.  Orally administered microencapsulated Bordetella pertussis fimbriae protect mice from B. pertussis respiratory infection , 1996, Infection and immunity.

[73]  C. Kensil.  Saponins as vaccine adjuvants. , 1996, Critical reviews in therapeutic drug carrier systems.

[74]  D. O’hagan.  The intestinal uptake of particles and the implications for drug and antigen delivery. , 1996, Journal of anatomy.

[75]  D. Ruble,et al.  Humoral immunity to aerosolized staphylococcal enterotoxin B (SEB), a superantigen, in monkeys vaccinated with SEB toxoid-containing microspheres , 1995, Infection and immunity.

[76]  C. Dekker,et al.  A Recombinant Glycoprotein Vaccine for Herpes Simplex Type 2: Safety and Efficacy , 1995, Annals of Internal Medicine.

[77]  J. Clements,et al.  Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity , 1995, Infection and immunity.

[78]  G. Bishop,et al.  CpG motifs in bacterial DNA trigger direct B-cell activation , 1995, Nature.

[79]  J. Eldridge,et al.  Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly(DL-lactide-co-glycolide) microspheres , 1995, Infection and immunity.

[80]  G. Dougan,et al.  Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[81]  J. T. Ulrich,et al.  Monophosphoryl Lipid A as an Adjuvant , 1995 .

[82]  K. Mills,et al.  Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles. , 1995, Vaccine.

[83]  R. Wagner,et al.  Priming of class I-restricted cytotoxic T lymphocytes by vaccination with recombinant protein antigens. , 1995, Vaccine.

[84]  K. Mills,et al.  Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells. , 1995, Vaccine.

[85]  H. Okada,et al.  Biodegradable microspheres in drug delivery. , 1995, Critical reviews in therapeutic drug carrier systems.

[86]  C. Kensil,et al.  Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function. , 1995, Vaccine.

[87]  F. Vogel,et al.  A compendium of vaccine adjuvants and excipients. , 1995, Pharmaceutical biotechnology.

[88]  G. Ott,et al.  Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. , 1995, Vaccine.

[89]  M. Powell,et al.  Vaccine Design , 1995, Pharmaceutical Biotechnology.

[90]  J. Kahn,et al.  Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers. , 1994, The Journal of infectious diseases.

[91]  B. Savarese,et al.  Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes , 1994, The Lancet.

[92]  D. O’hagan.  Novel Delivery Systems for Oral Vaccines , 1994 .

[93]  D. O'hagan,et al.  Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. , 1994, Immunology.

[94]  C. Kensil,et al.  Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. , 1994, Vaccine.

[95]  Seamus J. Martin,et al.  Immunization of human HIV‐seronegative volunteers with recombinant p17/p24: Ty virus‐like particles elicits HIV‐1 p24‐specific cellular and humoral immune responses , 1993, AIDS.

[96]  M. Reddish,et al.  Immune Responses of Mice and Human Breast Cancer Patients following Immunization with Synthetic Sialyl‐Tn Conjugated to KLH Plus Detox Adjuvant , 1993, Annals of the New York Academy of Sciences.

[97]  A. Gettie,et al.  Protection against vaginal SIV transmission with microencapsulated vaccine. , 1993, Science.

[98]  S. Davis,et al.  Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles. , 1993, Vaccine.

[99]  G. Poste,et al.  New Generation Vaccines , 1993, NATO ASI Series.

[100]  C. Alving,et al.  Immunologic aspects of liposomes: presentation and processing of liposomal protein and phospholipid antigens. , 1992, Biochimica et biophysica acta.

[101]  D. Rahman,et al.  Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen. , 1992, Immunology.

[102]  G. Gustafson,et al.  Bacterial cell wall products as adjuvants: early interferon gamma as a marker for adjuvants that enhance protective immunity. , 1992, Research in immunology.

[103]  S. Davis,et al.  Controlled release microparticles for vaccine development. , 1991, Vaccine.

[104]  D. Pisetsky,et al.  Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. , 1991, Journal of immunology.

[105]  Eldridge,et al.  Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies , 1991, Infection and immunity.

[106]  S. Romagnani.  Human TH1 and TH2 subsets: doubt no more. , 1991, Immunology today.

[107]  D. Rahman,et al.  Biodegradable microparticles as controlled release antigen delivery systems. , 1991, Immunology.

[108]  T. Mosmann,et al.  The role of IL-10 in crossregulation of TH1 and TH2 responses. , 1991, Immunology today.

[109]  Gary J. Nabel,et al.  New Generation Vaccines , 1990 .

[110]  Thomas R. Tice,et al.  Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the peyer's patches , 1990 .

[111]  G. Gregoriadis.  Immunological adjuvants: a role for liposomes. , 1990, Immunology today.

[112]  T. Mosmann,et al.  Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies , 1987, The Journal of experimental medicine.

[113]  W. Paul,et al.  Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. , 1987, Science.

[114]  A. Bird.  CpG islands as gene markers in the vertebrate nucleus , 1987 .

[115]  R. Coffman,et al.  Two types of mouse helper T-cell clone Implications for immune regulation. , 1987, Immunology today.

[116]  A. Allison,et al.  An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity. , 1986, Journal of immunological methods.

[117]  Y. Fujisawa,et al.  Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. , 1984, Journal of the National Cancer Institute.

[118]  B D Hall,et al.  Synthesis and assembly of hepatitis B virus surface antigen particles in yeast , 1982, Nature.